Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Orna Therapeutics
Biotech
BIO, Seaport, Orna and more—Chutes & Ladders
Top BIO lobbyist swiftly departs after BIOSECURE reversal. Karuna leaders launch new venture after BMS buyout. Orna snags top Kite exec as CMO.
Max Bayer
,
Gabrielle Masson
Apr 12, 2024 8:30am
ReNAgade lays off 10% of staff 6 months after $300M series A
Dec 5, 2023 10:15am
New RNA biotech raises $300M in largest private round of 2023
May 23, 2023 6:30am
Biotech's top money raisers: 2022
Apr 11, 2023 9:19am
Merck bets big on circular RNA, paying $150M to work with Orna
Aug 16, 2022 9:00am
Orna debuts with $100M, engineered circular RNA treatments
Feb 24, 2021 6:00am
